Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 4/2022

01-04-2022 | Literatur kommentiert

Genomische Klassifizierung und Überleben von Patienten mit Rhabdomyosarkom: Bericht eines internationalen Konsortiums

Author: PD Dr. med. Monika Sparber-Sauer

Published in: Strahlentherapie und Onkologie | Issue 4/2022

Login to get access

Auszug

Das Rhabdomyosarkom (RMS) ist das häufigste Weichteilsarkom im Kindesalter [1]. Trotz aggressiver Therapie ist die 5‑Jahres-Überlebensrate für Patienten mit metastasierter oder rezidivierender Erkrankung nach wie vor schlecht, und neben dem PAX-FOXO1-Fusionsstatus gibt es bisher keine genomischen Marker für die Risikoabschätzung. Shern et al. stellen nun eine internationale Studie zur Bestimmung der Häufigkeit von Treibermutationen („driver mutations“) und deren Zusammenhang mit dem Überleben vor. …
Literature
1.
2.
Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 59(1):5–10CrossRef
3.
Oberlin O et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26(14):2384–2389CrossRef
4.
Klingebiel T et al (2008) Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 50(4):739–745CrossRef
5.
Meza JL et al (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 24(24):3844–3851CrossRef
6.
Newton WA Jr. et al (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. Cancer 76(6):1073–1085CrossRef
7.
Barr FG (1997) Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 19(6):483–491CrossRef
8.
Pappo AS, Shapiro DN, Crist WM (1997) Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 44(4):953–972CrossRef
9.
Hibbitts E et al (2019) Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the children’s oncology group. Cancer Med 8(14):6437–6448CrossRef
10.
Missiaglia E et al (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30(14):1670–1677CrossRef
11.
12.
Skapek SX et al (2013) PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer 60(9):1411–1417CrossRef
13.
Bisogno G et al (2021) Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas. Pediatr Blood Cancer 68(7):e28951CrossRef
14.
Bisogno G et al (2020) A new standard of care for patients with high-risk rhabdomyosarcoma?—Authors’ reply. Lancet Oncol 21(1):e3CrossRef
15.
Bisogno G et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(11):1566–1575CrossRef
16.
Shern JF et al (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4(2):216–231CrossRef
17.
Seki M et al (2015) Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 6:7557CrossRef
18.
Chen L et al (2015) Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet 11(3):e1005075CrossRef
19.
Stratton MR et al (1989) Detection of point mutations in N‑ras and K‑ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 49(22):6324–6327PubMed
20.
Chen X et al (2013) Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24(6):710–724CrossRef
21.
Malempati S et al (2011) Rhabdomyosarcoma in infants younger than 1 year: a report from the Children’s Oncology Group. Cancer 117(15):3493–3501CrossRef
22.
Joshi D et al (2004) Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer 42(1):64–73CrossRef
23.
Sparber-Sauer M et al (2019) Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer 66(6):e27652CrossRef
24.
Li FP, Fraumeni JF Jr. (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43(6):1365–1373PubMed
25.
Kohsaka S et al (2014) A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46(6):595–600CrossRef
26.
Casey DL et al (2020) Genomic determinants of clinical outcomes in rhabdomyosarcoma. Clin Cancer Res 26(5):1135–1140CrossRef
Metadata
Title
Genomische Klassifizierung und Überleben von Patienten mit Rhabdomyosarkom: Bericht eines internationalen Konsortiums
Author
PD Dr. med. Monika Sparber-Sauer
Publication date
01-04-2022
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 4/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-01908-3

Other articles of this Issue 4/2022

Strahlentherapie und Onkologie 4/2022 Go to the issue

Literatur kommentiert

Kein Vorteil für die lokale Kontrolle nach Dosiseskalation der Strahlentherapie bei Patienten mit Ösophaguskarzinom nach einer definitiven Radiochemotherapie: randomisierte Phase-III-Studie ARTDECO

Review Article

125 years of head and neck radiotherapy: could organ-sparing radiotherapy of larynx cancer have prevented World War I?

Original Article

Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients

Original Article

Coronavirus disease 2019 and radiation oncology—survey on the impact of the severe acute respiratory syndrome coronavirus 2 pandemic on health care professionals in radiation oncology

Literatur kommentiert

Deeskalation der adjuvanten Radiotherapie nach transoraler Resektion HPV-positiver Oropharynxkarzinome: Ergebnisse der E3311-Studie

Original Article

ArthroRad trial: multicentric prospective and randomized single-blinded trial on the effect of low-dose radiotherapy for painful osteoarthritis depending on the dose—results after 3 months’ follow-up